Early Signs of PML in Tysabri Patients: What to Watch For

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Occupational Exposure

If you or a loved one is taking Tysabri, recognizing early signs of progressive multifocal leukoencephalopathy (PML) is critical. Subtle changes like confusion, vision problems, or weakness on one side can be the first clues. This page explains how PML is diagnosed and monitored, building on decades of research into disease-modifying therapies and their risks.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV), a pathogen that typically remains dormant in healthy individuals but can reactivate in immunocompromised patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable and often insidious. Patients may develop progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, visual changes, or speech difficulties. In the context of Tysabri therapy, the onset of PML can be difficult to distinguish from multiple sclerosis relapse, which is a common adverse event reported in FAERS data (16,691 reports of multiple sclerosis relapse) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). Other frequently reported symptoms in Tysabri-treated patients include fatigue (19,150 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and balance disorder (5,621 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These overlapping symptoms underscore the diagnostic challenge of PML in this population.

Diagnosis and Risk Factors for Tysabri-Associated PML

Diagnosis of PML relies on neuroimaging, typically brain MRI showing characteristic white matter lesions, and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). The FDA-approved label emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, the label acknowledges that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for Tysabri-associated PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist, which inhibits lymphocyte trafficking across the blood-brain barrier. This immunosuppressive effect within the central nervous system reduces immune surveillance, allowing JCV to reactivate and cause lytic infection of oligodendrocytes. The resulting demyelination produces the clinical syndrome of PML.

Legal Implications and Statute of Limitations in Pennsylvania

The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations for affected patients. The boxed warning is prominently displayed in the prescribing information, and the drug is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers adequately communicated the risk of PML, particularly in patients who developed the disease despite being considered low-risk based on anti-JCV antibody status or short treatment duration. For patients in Pennsylvania who have developed PML after Tysabri exposure, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Pennsylvania, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. The timeline between Tysabri exposure and documented harm is variable; PML can occur after a few months to several years of treatment, as noted in the label for herpes infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate the determination of when the statute of limitations begins to run. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to assess the specific facts of their case, including the date of diagnosis, the duration of Tysabri therapy, and any prior immunosuppressant use.

Adverse Event Profile and Risk-Benefit Considerations

The risk-benefit profile of Tysabri requires careful consideration. While the drug can be effective for multiple sclerosis, the risk of PML is a serious and potentially fatal adverse effect. The FDA's FAERS data show that Tysabri is associated with a wide range of adverse events, including cognitive disorder (3,478 reports), depression (3,091 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports, while not necessarily causally linked to PML, highlight the overall burden of adverse effects in this patient population. In summary, Tysabri-associated PML is a devastating complication with a well-characterized risk profile. The drug's labeling provides explicit warnings, but the adequacy of those warnings in individual cases may be subject to legal scrutiny. Pennsylvania patients who have developed PML should be aware of the statute of limitations and seek timely legal advice. The mechanistic link between Tysabri and PML is grounded in its immunosuppressive effects on the central nervous system, and the clinical presentation requires prompt recognition and intervention to improve outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury actions, including product liability and medical malpractice claims related to Tysabri and PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. Given the variable latency of PML, it is crucial to consult an attorney promptly after diagnosis to ensure compliance with this deadline.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for Tysabri-associated PML are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with these factors should be monitored closely for any signs of PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.